Literature DB >> 6223813

In vitro activity of seventeen antimicrobial agents against Gardnerella vaginalis.

S Shanker, M Toohey, R Munro.   

Abstract

The in vitro activity of 17 antimicrobial agents was tested against 25 clinical isolates of Gardnerella vaginalis. Minimum inhibitory concentrations were determined by agar dilution. The isolates were sensitive to penicillin, ampicillin, ticarcillin, piperacillin, cephalothin, cefoxitin, cefotaxime, cefoperazone, N-formimidoyl-thienamycin, chloramphenicol, clindamycin and erythromycin. MIC90 for the beta-lactam antibiotics ranged from 0.12 mg/l for penicillin to 2 mg/l for ticarcillin. Cefoperazone was the most active cephalosporin, inhibiting all isolates at 1.0 mg/l. N-formimidoylthienamycin was the most active of the newer beta-lactam compounds inhibiting all isolates with a concentration of 0.5 mg/l. Clindamycin and erythromycin were highly active, inhibiting all isolates at 0.6 mg/l. Susceptibility to tetracycline, gentamicin, metronidazole and tinidazole varied between strains. All isolates were resistant to rosoxacin. The hydroxy-metabolites of metronidazole and tinidazole were more active than the parent compounds, inhibiting all isolates.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6223813     DOI: 10.1007/bf02019975

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  20 in total

1.  Rapid hippurate hydrolysis method for presumptive identification of group B streptococci.

Authors:  M N Hwang; G M Ederer
Journal:  J Clin Microbiol       Date:  1975-01       Impact factor: 5.948

2.  Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified non-specific vaginitis.

Authors:  H L GARDNER; C D DUKES
Journal:  Am J Obstet Gynecol       Date:  1955-05       Impact factor: 8.661

3.  Heamophilus vaginalis (Corynebacterium vaginal): method for isolation and rapid biochemical identification.

Authors:  J R Greenwood; M J Pickett; W J Martin; E G Mack
Journal:  Health Lab Sci       Date:  1977-04

4.  Gardnerella vaginalis, anaerobes, and vaginal discharge.

Authors:  E Taylor; A L Blackwell; D Barlow; I Phillips
Journal:  Lancet       Date:  1982-06-19       Impact factor: 79.321

5.  Nonspecific vaginitis: role of Haemophilus vaginalis and treatment with metronidazole.

Authors:  T A Pheifer; P S Forsyth; M A Durfee; H M Pollock; K K Holmes
Journal:  N Engl J Med       Date:  1978-06-29       Impact factor: 91.245

6.  Anaerobic bacteria in nonspecific vaginitis.

Authors:  C A Spiegel; R Amsel; D Eschenbach; F Schoenknecht; K K Holmes
Journal:  N Engl J Med       Date:  1980-09-11       Impact factor: 91.245

7.  Antibiotic susceptibility of Haemophilus vaginalis (Corynebacterium vaginale) to 21 antibiotics.

Authors:  L R McCarthy; P A Mickelsen; E G Smith
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

8.  Metronidazole metabolite and Gardnerella vaginalis (Corynebacterium vaginale)

Authors:  M J Baldson; D Jackson
Journal:  Lancet       Date:  1981-05-16       Impact factor: 79.321

9.  Ineffectiveness of erythromycin for treatment of Haemophilus vaginalis-associated vaginitis: possible relationship to acidity of vaginal secretions.

Authors:  M A Durfee; P S Forsyth; J A Hale; K K Holmes
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

10.  In vitro antimicrobial activity of rosoxacin against Neisseria gonorrhoeae, Chlamydia trachomatis, and Ureaplasma urealyticum.

Authors:  R A Dobson; J R O'Connor; S A Poulin; R B Kundsin; T F Smith; P E Came
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

View more
  9 in total

1.  In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

2.  Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole.

Authors:  M N Austin; R H Beigi; L A Meyn; S L Hillier
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

3.  In vitro activity of ciprofloxacin and norfloxacin against Gardnerella vaginalis.

Authors:  K Machka
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

Review 4.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

5.  Longitudinal study of the biotypes of Gardnerella vaginalis.

Authors:  A M Briselden; S L Hillier
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

6.  In vitro activity of azithromycin and erythromycin against organisms associated with bacterial vaginosis and chancroid.

Authors:  B M Jones; G R Kinghorn; B I Duerden
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

7.  The inhibitory effect of clindamycin on Lactobacillus in vitro.

Authors:  A Aroutcheva; J A Simoes; S Shott; S Faro
Journal:  Infect Dis Obstet Gynecol       Date:  2001

Review 8.  On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections.

Authors:  R Matthew Chico; Berkin B Hack; Melanie J Newport; Enesia Ngulube; Daniel Chandramohan
Journal:  Expert Rev Anti Infect Ther       Date:  2013-11-06       Impact factor: 5.091

Review 9.  Determination and Identification of Antibiotic Drugs and Bacterial Strains in Biological Samples.

Authors:  Katarzyna Pauter; Małgorzata Szultka-Młyńska; Bogusław Buszewski
Journal:  Molecules       Date:  2020-05-31       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.